MedPath

Comparision Of Efficay And Adverse Effects Of Two Topicals In Treatment Of Localised Alopecia Areata - METHOTREXATE ONE PERCENTAGE GEL TOFACITINIB Versus TWO PERCENTAGE GE

Not Applicable
Conditions
Health Condition 1: L638- Other alopecia areata
Registration Number
CTRI/2024/06/069460
Lead Sponsor
DR M Yashaswini
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Patients of more than 18 Years.

2.Patients of both the genders.

3.Patients of localised alopecia over any part of the body.

Exclusion Criteria

1.Patients with other systemic illness-Cardiac, Renal, Hepatic Illness.

2.Severely immunocompromised.

3.Pregnancy.

4.Patients who have undergone treatment recently with other modalities in Past 6 weeks.

5.PATIENT NOT GIVING CONSENT FOR THE STUDY

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Trichoscopic Evaluation . <br/ ><br>Lesional Area Density (LAD) SCORE. <br/ ><br>Global Photographic Assessment (GPA) ScaleTimepoint: Baseline . <br/ ><br>Two weeks. <br/ ><br>Four weeks. <br/ ><br>Six weeks. <br/ ><br>Eight weeks . <br/ ><br>Ten weeks. <br/ ><br>Twelve weeks . <br/ ><br>Fourteen weeks. <br/ ><br>Sixteen weeks. <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
Post treatment adverse effects & efficacy of TOFACITINIB 2% GEL & METHOTREXATE 1 % GELTimepoint: Follow up visit for every 2 weeks i.e, 2,4,6,8 till 8 weeks
© Copyright 2025. All Rights Reserved by MedPath